| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Tiziana Life Sciences completes Covid-19 antibody clinical trial in Brazil
StockMarketWire.com
|
Biotechnology company Tiziana Life Sciences said it had completed its clinical trial of Foralumab, a monoclonal antibody to treat COVID-19 patients in Brazil.
The topline data from the trial was expected to be available in January 2021, the company said.
'Because COVID-19 enters through the nasal and respiratory passage, the proprietary nasal formulation and nasal delivery of Foralumab is an innovative approach to provide immediate relief to COVID-19 patients,' it added.
At 9:26am: (LON:TILS) Tiziana Life Sciences Plc share price was 0p at 92p
Story provided by StockMarketWire.com
|
|
|
|
|
|
